SCHOFIELD, Wis., July 20, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) is announcing that an independent clinical study of its non-prescription migraine medication LipiGesic™ M conducted by leading headache researcher Dr. Roger Cady, has now been published in the recent July/August print edition of Headache, a top-tier medical journal of the American Headache Society.
The study found that 64 percent of subjects found pain relief within two hours of taking LipiGesic™ M and confirms that sublingual feverfew/ginger is safe and effective as a first-line treatment for a population of migraineurs who frequently experience mild headache prior to the onset of moderate to severe headache.
"We are pleased that the independent clinical results for LipiGesic™ M are now available in the recent print issue of Headache," said PuraMed BioScience CEO Russell Mitchell. In addition, the leading headache researcher Dr. Roger Cady, MD last week exhibited a poster presentation of his independent clinical study of PuraMed's non-prescription migraine medication LipiGesic™M at the 2011 Headache Update Conference that received a large amount of attention and adulation from the medical community. The enormously positive response we received from this group of nationally recognized headache specialists exceeded our highest expectations and reinforced our belief that our product, LipiGesic™M, will truly be the new first-line defense against migraines."
Mitchell continued, "In addition to the higher efficacy rate, the study subjects reported minimal to no side effects. The study states that there remains a need for affordable, effective treatments for migraine sufferers. It is with this in mind that we have been exploring opportunities to bring LipiGesic™M to the retail market and believe we are strongly positioned to do so in the near term."
For more information on LipiGesic™ M and to purchase, visit www.LipiGesicM.com.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.